<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04457258</url>
  </required_header>
  <id_info>
    <org_study_id>20-000623</org_study_id>
    <secondary_id>NCI-2020-03767</secondary_id>
    <secondary_id>20-000623</secondary_id>
    <nct_id>NCT04457258</nct_id>
  </id_info>
  <brief_title>68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma</brief_title>
  <official_title>PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Sarcoma: An Exploratory Biodistribution Study With Histopathology Validation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This early phase I trial studies an imaging technique called 68Ga-FAPi-46 PET/CT to determine
      where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer
      tissues in patients with sarcoma. PET is an established imaging technique that utilizes small
      amounts of radioactivity attached to very minimal amounts of tracer, in the case of this
      research, 68Ga-FAPi. Because some cancers take up 68Ga-FAPi it can be seen with PET. CT
      utilizes x-rays that traverse body from the outside. CT images provide an exact outline of
      organs and potential inflammatory tissue where it occurs in patient's body.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. To define the biodistribution of gallium Ga 68 fibroblast activation protein inhibitor
      (FAPi)-46 (68Ga-FAPi-46) in normal and cancer tissues of patients with sarcoma with
      histopathology validation.

      SECONDARY OBJECTIVES:

      I. To evaluate whether 68Ga-FAPi-46 accumulation observed by positron emission tomography
      (PET) reflects geography, extent and degree of FAP expression determined by
      immuno-histochemistry (IHC).

      II. To assess the 68Ga-FAPI-46 biodistribution correlation with fludeoxyglucose F-18
      (18F-FDG) biodistribution and to define the frequency of the following phenotypes (FAP
      positive [+]/ FDG+, FAP negative [-]/ FDG+, FAP+/ FDG-, FAP-/ FDG-).

      OUTLINE:

      Patients receive 68Ga-FAPi-46 intravenously (IV), and then undergo PET/computed tomography
      (CT) over 20-90 minutes.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">July 21, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biodistribution of gallium Ga 68 fibroblast activation protein inhibitor (FAPi)-46 (68Ga-FAPi-46) in normal and cancer tissues</measure>
    <time_frame>At 20-90 minutes after injection</time_frame>
    <description>Will be quantified by mean and maximum standardized uptake values (SUVmean and SUVmax).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>68Ga-FAPi-46 accumulation observed by positron emission tomography (PET)/computed tomography (CT)</measure>
    <time_frame>Up to year 2</time_frame>
    <description>Will be correlated with and validated by FAP expression in surgically removed or biopsy derived tumor tissue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of the following phenotypes (FAP positive [+]/ fludeoxyglucose [FDG]+, FAP negative [-]/ FDG+, FAP+/ FDG-, FAP-/ FDG-)</measure>
    <time_frame>Up to year 2</time_frame>
    <description>Assessed by 68Ga-FAPI-46 biodistribution correlation with fludeoxyglucose F-18 (18F-FDG) biodistribution.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Metastatic Sarcoma</condition>
  <condition>Recurrent Sarcoma</condition>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (68Ga-FAPI-46 PET/CT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 68Ga-FAPi-46 IV, and then undergo PET/CT over 20-90 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo PET/CT</description>
    <arm_group_label>Diagnostic (68Ga-FAPI-46 PET/CT)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>Computerized Tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT Scan</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gallium Ga 68 FAPi-46</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (68Ga-FAPI-46 PET/CT)</arm_group_label>
    <other_name>68Ga-FAPi-46</other_name>
    <other_name>Gallium-68-FAPi-46</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo PET/CT</description>
    <arm_group_label>Diagnostic (68Ga-FAPI-46 PET/CT)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who underwent a 18F-FDG PET/CT scan within 3 months of enrollment.

          -  Patients who are scheduled to undergo surgical excision or biopsy of a sarcoma
             primary, recurrent or metastatic lesion.

          -  Patients who can provide written informed consent.

          -  Patients who are able to remain still for duration of imaging procedure (up to one
             hour).

        Exclusion Criteria:

          -  Patients with any new sarcoma therapy between the 18F-FDG PET/CT and the FAPI PET/CT.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremie Calais</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA / Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA / Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jeremie Calais</last_name>
      <phone>310-825-3617</phone>
      <email>jcalais@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Jeremie Calais</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 30, 2020</study_first_submitted>
  <study_first_submitted_qc>June 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

